Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus
Exosomes, nanometer-sized lipid-bilayer-enclosed extracellular vesicles (EVs), have attracted increasing attention due to their inherent ability to shuttle proteins, lipids and genes between cells and their natural affinity to target cells. Their intrinsic features such as stability, biocompatibilit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/1/3 |
| _version_ | 1797543907197714432 |
|---|---|
| author | Ana Ortega Olga Martinez-Arroyo Maria J. Forner Raquel Cortes |
| author_facet | Ana Ortega Olga Martinez-Arroyo Maria J. Forner Raquel Cortes |
| author_sort | Ana Ortega |
| collection | DOAJ |
| description | Exosomes, nanometer-sized lipid-bilayer-enclosed extracellular vesicles (EVs), have attracted increasing attention due to their inherent ability to shuttle proteins, lipids and genes between cells and their natural affinity to target cells. Their intrinsic features such as stability, biocompatibility, low immunogenicity and ability to overcome biological barriers, have prompted interest in using exosomes as drug delivery vehicles, especially for gene therapy. Evidence indicates that exosomes play roles in both immune stimulation and tolerance, regulating immune signaling and inflammation. To date, exosome-based nanocarriers delivering small molecule drugs have been developed to treat many prevalent autoimmune diseases. This review highlights the key features of exosomes as drug delivery vehicles, such as therapeutic cargo, use of targeting peptide, loading method and administration route with a broad focus. In addition, we outline the current state of evidence in the field of exosome-based drug delivery systems in systemic lupus erythematosus (SLE), evaluating exosomes derived from various cell types and engineered exosomes. |
| first_indexed | 2024-03-10T13:52:07Z |
| format | Article |
| id | doaj.art-3af7d053449e449f9b3680b68771b55f |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T13:52:07Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-3af7d053449e449f9b3680b68771b55f2023-11-21T01:59:35ZengMDPI AGPharmaceutics1999-49232020-12-01131310.3390/pharmaceutics13010003Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus ErythematosusAna Ortega0Olga Martinez-Arroyo1Maria J. Forner2Raquel Cortes3Cardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, 46010 Valencia, SpainCardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, 46010 Valencia, SpainCardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, 46010 Valencia, SpainCardiometabolic and Renal Risk Research Group, INCLIVA Biomedical Research Institute, 46010 Valencia, SpainExosomes, nanometer-sized lipid-bilayer-enclosed extracellular vesicles (EVs), have attracted increasing attention due to their inherent ability to shuttle proteins, lipids and genes between cells and their natural affinity to target cells. Their intrinsic features such as stability, biocompatibility, low immunogenicity and ability to overcome biological barriers, have prompted interest in using exosomes as drug delivery vehicles, especially for gene therapy. Evidence indicates that exosomes play roles in both immune stimulation and tolerance, regulating immune signaling and inflammation. To date, exosome-based nanocarriers delivering small molecule drugs have been developed to treat many prevalent autoimmune diseases. This review highlights the key features of exosomes as drug delivery vehicles, such as therapeutic cargo, use of targeting peptide, loading method and administration route with a broad focus. In addition, we outline the current state of evidence in the field of exosome-based drug delivery systems in systemic lupus erythematosus (SLE), evaluating exosomes derived from various cell types and engineered exosomes.https://www.mdpi.com/1999-4923/13/1/3extracellular vesiclesexosomesmicroparticlesdrug deliverytherapyautoimmunity |
| spellingShingle | Ana Ortega Olga Martinez-Arroyo Maria J. Forner Raquel Cortes Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus Pharmaceutics extracellular vesicles exosomes microparticles drug delivery therapy autoimmunity |
| title | Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus |
| title_full | Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus |
| title_fullStr | Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus |
| title_full_unstemmed | Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus |
| title_short | Exosomes as Drug Delivery Systems: Endogenous Nanovehicles for Treatment of Systemic Lupus Erythematosus |
| title_sort | exosomes as drug delivery systems endogenous nanovehicles for treatment of systemic lupus erythematosus |
| topic | extracellular vesicles exosomes microparticles drug delivery therapy autoimmunity |
| url | https://www.mdpi.com/1999-4923/13/1/3 |
| work_keys_str_mv | AT anaortega exosomesasdrugdeliverysystemsendogenousnanovehiclesfortreatmentofsystemiclupuserythematosus AT olgamartinezarroyo exosomesasdrugdeliverysystemsendogenousnanovehiclesfortreatmentofsystemiclupuserythematosus AT mariajforner exosomesasdrugdeliverysystemsendogenousnanovehiclesfortreatmentofsystemiclupuserythematosus AT raquelcortes exosomesasdrugdeliverysystemsendogenousnanovehiclesfortreatmentofsystemiclupuserythematosus |